Intensive Blood Pressure Control in Isolated Systolic Hypertension: a Post Hoc Analysis of a Cluster Randomized Trial

Overview

Journal Lancet Reg Health West Pac

Date 2024 Jul 23

PMID 39040034

Authors

Chang Wang

Songyue Liu

Wei Miao

Ning Ye

Ziyi Xie

Lixia Qiao

Nanxiang Ouyang

Yangzhi Yin

Yingxian Sun

Guozhe Sun

Affiliations

Soon will be listed here.

Abstract

Background: The isolated systolic hypertension (ISH) is of high prevalence, with a relatively poor prognosis. However, there is still no direct evidence to demonstrate the benefits of intensive blood pressure (BP) control among these patients. We aimed to evaluate intensive BP control with the target of <130/80 mmHg in ISH.

Methods: This was a post hoc analysis of patients with ISH in the China Rural Hypertension Control Project (CRHCP), defined as systolic blood pressure (SBP) ≥ 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg. The primary outcome was cardiovascular disease (CVD) including stroke, myocardial infarction, heart failure, and CVD death. Mixed-effect Cox proportional regression and generalized estimating equation models were used for analysis.

Findings: In total, 7981 patients were randomly assigned to the intervention group and 8005 to the usual care group between May 8 and November 27, 2018. The median follow-up was 3.02 years (25-75%: 2.98-3.06). Mean systolic/diastolic BP at the end of 36 months follow-up was 126.5/71.2 mmHg in the intensive BP control group and 148.1/78.6 mmHg in the usual care group. The intervention group presented a substantially lower rate of composite CVD compared with the usual care group (1.52% versus 2.30%/year; multiple-adjusted hazard ratio (HR): 0.64; 95% confidence interval (CI): 0.57-0.72; < 0.001), especially for stroke (multiple-adjusted HR: 0.61; 95% CI: 0.53-0.70; < 0.001), HF (multiple-adjusted HR: 0.57; 95% CI: 0.36-0.91; = 0.017) and CVD death (multiple-adjusted HR: 0.64; 95% CI: 0.50-0.83; < 0.001). The primary composite outcome was substantially reduced by 36% in the intervention group compared with the usual care group. The further interaction analysis revealed that the reduction of primary outcome by intervention was consistent across subgroups of sex, age, education level, history of CVD, use of antihypertensive medication and baseline DBP ( > 0.05 for all interaction test). The incidences of symptomatic hypotension, syncope injurious falls and renal outcomes did not differ between the two groups, even though hypotension was increased in intervention group (RR:1.71; 95% CI: 1.28-2.28; < 0.001).

Interpretation: Intensive BP control (<130/80 mmHg) was effective and safe in patients with ISH for the prevention of CVD events.

Funding: The Ministry of Science and Technology (China) of China and the Science and Technology Program of Liaoning Province, China.

References

Franklin S, Jacobs M, Wong N, LItalien G, Lapuerta P . Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001; 37(3):869-74. DOI: 10.1161/01.hyp.37.3.869. View

Wills A, Lawlor D, Matthews F, Sayer A, Bakra E, Ben-Shlomo Y . Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. PLoS Med. 2011; 8(6):e1000440. PMC: 3114857. DOI: 10.1371/journal.pmed.1000440. View

Wijsman L, Muller M, de Craen A, Jukema J, Westendorp R, Mooijaart S . Association of diastolic blood pressure with cardiovascular events in older people varies upon cardiovascular history. J Hypertens. 2017; 36(4):773-778. DOI: 10.1097/HJH.0000000000001625. View

Medina-Inojosa J, Somers V, Garcia M, Thomas R, Allison T, Chaudry R . Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice. J Am Coll Cardiol. 2023; 82(15):1499-1508. DOI: 10.1016/j.jacc.2023.07.018. View

. The J-curve phenomenon and the treatment of hypertension. JAMA. 1991; 266(1):64-6. View

Wang L, Yang G, Jiemin M, Rao C, Wan X, Dubrovsky G . Evaluation of the quality of cause of death statistics in rural China using verbal autopsies. J Epidemiol Community Health. 2007; 61(6):519-26. PMC: 2465713. DOI: 10.1136/jech.2005.043927. View

Sun Y, Mu J, Wang D, Ouyang N, Xing L, Guo X . A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022; 399(10339):1964-1975. DOI: 10.1016/S0140-6736(22)00325-7. View

Pepine C, Handberg E, Cooper-DeHoff R, Marks R, Kowey P, Messerli F . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290(21):2805-16. DOI: 10.1001/jama.290.21.2805. View

Farnett L, Mulrow C, Linn W, Lucey C, Tuley M . The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?. JAMA. 1991; 265(4):489-95. View

10.

Franklin S, Barboza M, Pio J, Wong N . Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. J Hypertens. 2006; 24(10):2009-16. DOI: 10.1097/01.hjh.0000244950.72664.02. View

11.

Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox K, Tardif J . Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016; 388(10056):2142-2152. DOI: 10.1016/S0140-6736(16)31326-5. View

12.

Staessen J, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhager W . Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350(9080):757-64. DOI: 10.1016/s0140-6736(97)05381-6. View

13.

Egan B, Li J, Shatat I, Fuller J, Sinopoli A . Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014; 129(20):2052-61. PMC: 4413456. DOI: 10.1161/CIRCULATIONAHA.113.007699. View

14.

Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-85. PMC: 4123215. DOI: 10.1056/NEJMoa1001286. View

15.

Messerli F, Panjrath G . The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?. J Am Coll Cardiol. 2009; 54(20):1827-34. DOI: 10.1016/j.jacc.2009.05.073. View

16.

Cheng S, Xanthakis V, Sullivan L, Vasan R . Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. Hypertension. 2012; 60(6):1393-9. PMC: 3499677. DOI: 10.1161/HYPERTENSIONAHA.112.201780. View

17.

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A . 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal.... J Hypertens. 2023; 41(12):1874-2071. DOI: 10.1097/HJH.0000000000003480. View

18.

Witham M, Price R, Struthers A, Donnan P, Messow C, Ford I . Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med. 2013; 173(18):1672-9. DOI: 10.1001/jamainternmed.2013.9043. View

19.

Flint A, Conell C, Ren X, Banki N, Chan S, Rao V . Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. N Engl J Med. 2019; 381(3):243-251. DOI: 10.1056/NEJMoa1803180. View

20.

Yang G, Rao C, Ma J, Wang L, Wan X, Dubrovsky G . Validation of verbal autopsy procedures for adult deaths in China. Int J Epidemiol. 2005; 35(3):741-8. DOI: 10.1093/ije/dyi181. View